{"id":617566,"date":"2022-09-20T20:20:01","date_gmt":"2022-09-20T20:20:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=617566"},"modified":"2022-09-20T20:20:01","modified_gmt":"2022-09-20T20:20:01","slug":"dermatomyositis-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-priovant-therapeutics-inc-corbus-pharmaceuticals-csl-behring","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dermatomyositis-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-priovant-therapeutics-inc-corbus-pharmaceuticals-csl-behring_617566.html","title":{"rendered":"Dermatomyositis Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies &#8211; Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1663676473.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dermatomyositis Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring\" src=\"https:\/\/www.abnewswire.com\/uploads\/1663676473.jpeg\" alt=\"Dermatomyositis Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cDermatomyositis Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Dermatomyositis market<\/a><\/strong> is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dermatomyositis pipeline products will significantly revolutionize the Dermatomyositis market dynamics.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Dermatomyositis is a type of inflammatory myopathy characterized by inflammatory and degenerative changes of the muscles and skin. Associated symptoms and physical findings may vary widely from case to case as patients may present differently. Muscle abnormalities may begin with aches and weakness of the muscles of the trunk, upper arms, hips, and thighs (proximal muscles).&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Dermatomyositis Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Dermatomyositis market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period<strong> (2019-2032)<\/strong>&nbsp;<\/li>\n<li>The cause of dermatomyositis is unknown, several genetic, immunologic, and environmental factors are implicated in this condition&nbsp;<\/li>\n<li>As per Waseem, Dermatomyositis is more common in women than in men, with incidence rates being<strong> 3.98<\/strong> and <strong>4.68<\/strong> per <strong>1,000,000<\/strong> respectively&nbsp;<\/li>\n<li><strong>Key Dermatomyositis Companies:<\/strong>&nbsp; Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, and others&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<\/li>\n<li><strong>Key Dermatomyositis Therapies:<\/strong>&nbsp; Brepocitinib, Lenabasum, HIZENTRA, and others&nbsp;<\/li>\n<li>The Dermatomyositis epidemiology based on gender analyzed that dermatomyositis is more common in women than in men (2:1)<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dermatomyositis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Dermatomyositis Market Report<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Dermatomyositis Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Dermatomyositis market report covers a descriptive overview and comprehensive insight of the Dermatomyositis Epidemiology and Dermatomyositis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Dermatomyositis market report provides insights on the current and emerging therapies.<\/li>\n<li>Dermatomyositis market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Dermatomyositis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Dermatomyositis market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about Dermatomyositis therapies set to grab major Dermatomyositis market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dermatomyositis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Dermatomyositis market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Dermatomyositis market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Dermatomyositis<\/li>\n<li>Prevalent Cases of Dermatomyositis by severity<\/li>\n<li>Gender-specific Prevalence of Dermatomyositis<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Dermatomyositis&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Dermatomyositis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as <strong>Brepocitinib, Lenabasum, HIZENTRA,<\/strong> and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Dermatomyositis epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dermatomyositis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Dermatomyositis Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Therapies and Key Companies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Brepocitinib:<\/strong> Priovant Therapeutics, Inc.<\/li>\n<li><strong>Lenabasum:<\/strong> CorbusPharmaceuticals<\/li>\n<li><strong>HIZENTRA:<\/strong> CSL Behring<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Dermatomyositis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Dermatomyositis Companies:<\/strong>&nbsp; Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, and others<\/li>\n<li><strong>Key Dermatomyositis Therapies:<\/strong>&nbsp; Brepocitinib, Lenabasum, HIZENTRA, and others<\/li>\n<li><strong>Dermatomyositis Therapeutic Assessment:<\/strong>&nbsp; Dermatomyositis current marketed and Dermatomyositis emerging therapies<\/li>\n<li><strong>Dermatomyositis Market Dynamics:<\/strong>&nbsp; Dermatomyositis market drivers and barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong>&nbsp; SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Dermatomyositis&nbsp; Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\">1. Dermatomyositis Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Dermatomyositis<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Dermatomyositis<\/p>\n<p style=\"text-align: justify;\">4. Dermatomyositis Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Dermatomyositis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Dermatomyositis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Dermatomyositis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Dermatomyositis&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Dermatomyositis Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Dermatomyositis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Dermatomyositis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Dermatomyositis Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Dermatomyositis Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Dermatomyositis Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Dermatomyositis Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Dermatomyositis Market barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Dermatomyositis Appendix<\/p>\n<p style=\"text-align: justify;\">18. Dermatomyositis Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Dermatomyositis treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dermatomyositis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Dermatomyositis Medications<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dermatomyositis-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-priovant-therapeutics-inc-corbus-pharmaceuticals-csl-behring\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dermatomyositis-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-priovant-therapeutics-inc-corbus-pharmaceuticals-csl-behring\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cDermatomyositis Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dermatomyositis-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-priovant-therapeutics-inc-corbus-pharmaceuticals-csl-behring_617566.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-617566","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=617566"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617566\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=617566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=617566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=617566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}